219 related articles for article (PubMed ID: 22384056)
1. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity.
Lin JE; Snook AE; Li P; Stoecker BA; Kim GW; Magee MS; Garcia AV; Valentino MA; Hyslop T; Schulz S; Waldman SA
PLoS One; 2012; 7(2):e31686. PubMed ID: 22384056
[TBL] [Abstract][Full Text] [Related]
2. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
3. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
4. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
5. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
[TBL] [Abstract][Full Text] [Related]
6. Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier.
Han X; Mann E; Gilbert S; Guan Y; Steinbrecher KA; Montrose MH; Cohen MB
PLoS One; 2011 Jan; 6(1):e16139. PubMed ID: 21305056
[TBL] [Abstract][Full Text] [Related]
7. Guanylate cyclase C deficiency causes severe inflammation in a murine model of spontaneous colitis.
Harmel-Laws E; Mann EA; Cohen MB; Steinbrecher KA
PLoS One; 2013; 8(11):e79180. PubMed ID: 24244444
[TBL] [Abstract][Full Text] [Related]
8. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
Romi H; Cohen I; Landau D; Alkrinawi S; Yerushalmi B; Hershkovitz R; Newman-Heiman N; Cutting GR; Ofir R; Sivan S; Birk OS
Am J Hum Genet; 2012 May; 90(5):893-9. PubMed ID: 22521417
[TBL] [Abstract][Full Text] [Related]
9. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 facilitates neutrophil transmigration via myosin light chain kinase-dependent disruption of occludin, without altering epithelial permeability.
Lapointe TK; Buret AG
Am J Physiol Gastrointest Liver Physiol; 2012 Feb; 302(3):G343-51. PubMed ID: 22135309
[TBL] [Abstract][Full Text] [Related]
11. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
12. The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
Rappaport JA; Waldman SA
Front Oncol; 2018; 8():299. PubMed ID: 30131940
[TBL] [Abstract][Full Text] [Related]
13. Congenital secretory diarrhoea caused by activating germline mutations in GUCY2C.
Müller T; Rasool I; Heinz-Erian P; Mildenberger E; Hülstrunk C; Müller A; Michaud L; Koot BG; Ballauff A; Vodopiutz J; Rosipal S; Petersen BS; Franke A; Fuchs I; Witt H; Zoller H; Janecke AR; Visweswariah SS
Gut; 2016 Aug; 65(8):1306-13. PubMed ID: 25994218
[TBL] [Abstract][Full Text] [Related]
14. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
15. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
16. The effects and mechanisms of myeloid differentiation protein 2 on intestinal mucosal permeability in mice with chronic colitis.
Han C; Guan Q; Guo L; Yang Y; Ruan S; Zhang X
J Cell Physiol; 2019 Nov; 234(11):21089-21099. PubMed ID: 31032920
[TBL] [Abstract][Full Text] [Related]
17. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
18. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
19. AIM2 contributes to the maintenance of intestinal integrity via Akt and protects against Salmonella mucosal infection.
Hu GQ; Song PX; Li N; Chen W; Lei QQ; Yu SX; Zhang XJ; Du CT; Deng XM; Han WY; Yang YJ
Mucosal Immunol; 2016 Sep; 9(5):1330-9. PubMed ID: 26838050
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.
Conlin VS; Wu X; Nguyen C; Dai C; Vallance BA; Buchan AM; Boyer L; Jacobson K
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G735-50. PubMed ID: 19661153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
